« Return to News | CROs/Service Providers

Catalent Pharma and CTC BIO to partner in South Korea

Monday, September 17, 2012 11:21 AM

Catalent Pharma Solutions, a Somerset, N.J.-based developer of solutions and drug delivery technology, and CTC Bio, a drug and service provider based in Seoul, South Korea, have entered into a collaboration to provide optimal solutions to South Korean pharmaceutical companies seeking to commercialize solid oral dose and controlled release products in the U.S. and Europe.

Combining CTC Bio’s position in the region with Catalent’s expertise in controlled release formulations, manufacturing network and broad experience in global product launches will provide South Korean companies with access to international markets.  

“South Korea is a highly innovative region, developing new products and effective pharmaceutical formulations,” said H.R. Jeon, CSO of CTC Bio. “This collaboration with Catalent provides South Korean pharmaceutical customers with better access to the leading provider of innovative controlled release drug delivery technologies and supply capabilities. Catalent's breadth of services and reputation for successful new product launches in international markets makes them an ideal partner for us and our clients/partners in South Korea.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.